Aprea Therapeutics, Inc.(APRE)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

APRE Aprea Therapeutics, Inc.

盘后交易 05-28 17:10:52 EDT

0.9305

+0.0159

+1.74%

盘后0.9305

+0.00000.00%

16:10 EDT

最高0.9475	最低0.8833	成交量10.90万
今开0.9146	昨收0.9146	日振幅7.02%
总市值1,152万	流通市值809.11万	总股本1,238万
成交额10.06万	换手率1.25%	流通股本869.54万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"APRE","market":"US","secType":"STK","nameCN":"Aprea Therapeutics, Inc.","latestPrice":0.9305,"timestamp":1779998400000,"preClose":0.9146,"halted":0,"volume":109011,"hourTrading":{"tag":"盘后","latestPrice":0.9305,"preClose":0.9305,"latestTime":"16:10 EDT","volume":205,"amount":190.7525,"timestamp":1779999004844,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017384649026897032,"floatShares":8695400,"shares":12382776,"eps":-1.49,"marketStatus":"盘后交易","change":0.0159,"latestTime":"05-28 17:10:52 EDT","open":0.9146,"high":0.9475,"low":0.8833,"amount":100564,"amplitude":0.070195,"askPrice":1,"askSize":21,"bidPrice":0.838,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-1.49,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1780012800000},"marketStatusCode":4,"adr":0,"listingDate":1570075200000,"exchange":"NASDAQ","adjPreClose":0.9146,"preHourTrading":{"tag":"盘前","latestPrice":0.92,"preClose":0.9146,"latestTime":"04:51 EDT","volume":80,"amount":73.60000000000001,"timestamp":1779958267588,"change":0.0054,"changeRate":0.005904,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.9305,"preClose":0.9305,"latestTime":"16:10 EDT","volume":205,"amount":190.7525,"timestamp":1779999004844,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.641039,"impliedVol":4.309,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/APRE","defaultTab":"news","newsList":[{"id":"1101618876","title":"奥本海默首予Aprea Therapeutics跑赢大市评级 目标价5美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1101618876","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101618876?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:26","pubTimestamp":1778156785,"startTime":"0","endTime":"0","summary":"生物制药公司Aprea Therapeutics获得奥本海默首次覆盖，分析师给予\"跑赢大市\"评级，并设定5美元的目标股价。此次覆盖标志着华尔街机构对该公司在肿瘤治疗领域研发进展的关注。奥本海默在研报中指出，Aprea的核心管线聚焦于p53肿瘤抑制蛋白通路创新疗法，其先导候选药物展现出解决耐药性癌症治疗的潜力。随着多项临床试验数据的陆续披露，Aprea的p53再激活技术平台能否为肿瘤治疗带来突破性进展，将成为后续股价表现的关键驱动因素。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0963586101.USD","LU2125909247.SGD","LU1880398554.USD","LU1880398471.USD","LU0757428866.USD","LU2298321311.HKD","SG9999014005.SGD","LU2125909759.SGD","LU2125910179.SGD","LU2125909916.SGD","LU0012050646.USD","SGXZ81514606.USD","LU1892829315.USD","LU2360108059.USD","BK4120","LU1923622614.USD","SG9999014013.SGD","SGXZ99366536.SGD","LU1923621640.USD","LU2092937221.SGD","BK4139","SGXZ51526630.SGD","LU0106261612.USD","LU2308191902.HKD","APRE","LU2433249047.HKD","LU1815336091.USD","SG9999014021.USD","LU1923622291.USD","LU2125909593.SGD","LU2041044095.USD","LU2125910336.SGD","CLH","SG9999014039.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109897242","title":"Aprea Therapeutics将在ASCO 2026年会公布Wee1抑制剂APR-1051的Acesot-1051一期临床试验进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1109897242","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109897242?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:15","pubTimestamp":1776780912,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics宣布，将在2026年美国临床肿瘤学会（ASCO）年会上披露其创新药物APR-1051的最新临床数据。该药物作为Wee1抑制剂，目前正处于Acesot-1051一期临床试验阶段，此次更新将展示其在肿瘤治疗领域的潜在突破性进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175325317","title":"Aprea Therapeutics 公布Wee1抑制剂Apr-1051积极临床进展，在研I期试验中确认部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1175325317","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175325317?lang=zh_cn&edition=full","pubTime":"2026-03-30 20:06","pubTimestamp":1774872399,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051在正在进行的I期ACESOT-1051临床试验中展现出的积极初步临床活性。试验数据显示，该药物已在一名患者中观察到经确认的部分缓解，这标志着该药物研发的一个重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198770926","title":"Aprea Therapeutics公布2025年第四季度及全年财务业绩并更新公司进展","url":"https://stock-news.laohu8.com/highlight/detail?id=1198770926","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198770926?lang=zh_cn&edition=full","pubTime":"2026-03-16 20:35","pubTimestamp":1773664502,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc.近日披露了其2025财年第四季度及全年的财务报告，并同步分享了公司最新的运营动态。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614277080","title":"Aprea Therapeutics, Inc.股价重挫10.11% 市值跌16.77万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614277080","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614277080?lang=zh_cn&edition=full","pubTime":"2026-02-27 01:18","pubTimestamp":1772126334,"startTime":"0","endTime":"0","summary":"北京时间2026年02月27日01时18分，Aprea Therapeutics, Inc.股票出现异动，股价大幅下挫10.11%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为2.32%。其相关个股中，Curanex Pharmaceuticals Inc、Klotho Neurosciences Inc C/Wts 21/06/2029 、Liminatus Pharma Inc C/Wts 30/04/2030 涨幅较大，Curanex Pharmaceuticals Inc、Kairos Pharma, Ltd.、Cardio Diagnostics Holdings Inc.较为活跃，换手率分别为635.32%、99.04%、98.81%，振幅较大的相关个股有Curanex Pharmaceuticals Inc、Briacell Therapeutics Corp C/Wts 26/02/2026、Klotho Neurosciences Inc C/Wts 21/06/2029 ，振幅分别为59.81%、53.95%、50.06%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022701185497a73185&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022701185497a73185&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","APRE","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117590352","title":"Aprea Therapeutics公司：220毫克剂量水平观察到肿瘤缩小50%及CA-125生物标志物显著降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1117590352","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117590352?lang=zh_cn&edition=full","pubTime":"2026-02-18 21:03","pubTimestamp":1771419793,"startTime":"0","endTime":"0","summary":"在最新临床研究中，Aprea Therapeutics公司采用220毫克剂量治疗方案取得突破性进展。该剂量水平不仅实现肿瘤体积缩小达50%的显著效果，更令人瞩目的是观察到CA-125生物标志物水平的实质性下降。这一双重积极指标为卵巢癌等恶性肿瘤的靶向治疗开辟了新路径。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157749062","title":"Aprea Therapeutics宣布Wee1抑制剂Apr-1051取得新进展，ACESOT-1051试验中观察到第二例部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1157749062","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157749062?lang=zh_cn&edition=full","pubTime":"2026-02-18 21:01","pubTimestamp":1771419674,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司近日公布了其Wee1抑制剂候选药物Apr-1051的最新积极临床数据。在正在进行的ACESOT-1051临床试验中，研究观察到了额外的临床活性信号，其中包括第二例达到部分缓解（Partial Response）的病例。这一进展进一步支持了Apr-1051在目标患者群体中的治疗潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104981388","title":"Aprea Therapeutics强化DDR抗癌疗法全球专利布局，为管线拓展铺平道路","url":"https://stock-news.laohu8.com/highlight/detail?id=1104981388","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1104981388?lang=zh_cn&edition=full","pubTime":"2026-02-12 10:23","pubTimestamp":1770862993,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司近日宣布其DNA损伤应答（DDR）抗癌疗法全球专利组合实现重要拓展，这一战略举措将为公司研发管线的持续增长奠定坚实基础。通过加强知识产权保护，该公司在肿瘤治疗领域的技术壁垒得到进一步巩固，为未来创新疗法的商业化进程提供了有力支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134539572","title":"Aprea Therapeutics 宣布在评估Wee1抑制剂APR-1051的ACESOT-1051剂量递增试验中取得早期临床概念验证，首次扫描即观察到部分缓解","url":"https://stock-news.laohu8.com/highlight/detail?id=1134539572","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1134539572?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:31","pubTimestamp":1769693485,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc. 近日公布，其正在进行的ACESOT-1051剂量递增试验已获得早期临床概念验证数据。该试验旨在评估其Wee1抑制剂候选药物APR-1051。令人鼓舞的是，在首次疗效评估扫描中，已观察到一例患者出现部分缓解，这为药物的抗肿瘤活性提供了初步的积极信号。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131666754","title":"Aprea Therapeutics公司：2026年上半年将发布更多进展，年内完成剂量递增研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1131666754","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131666754?lang=zh_cn&edition=full","pubTime":"2026-01-29 21:29","pubTimestamp":1769693350,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics公司宣布，将在2026年上半年披露更多研发进展，并计划于同年晚些时候完成其正在进行的剂量递增研究。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109491456","title":"Aprea Therapeutics, Inc. - 提交股东5.5百万股的再销售招股说明书 - SEC备案","url":"https://stock-news.laohu8.com/highlight/detail?id=1109491456","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109491456?lang=zh_cn&edition=full","pubTime":"2025-12-20 05:14","pubTimestamp":1766178871,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics, Inc. - 提交股东5.5百万股的再销售招股说明书 - SEC备案","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147401439","title":"Aprea Therapeutics首席执行官致股东信，强调2025年管线进展及2026年展望","url":"https://stock-news.laohu8.com/highlight/detail?id=1147401439","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1147401439?lang=zh_cn&edition=full","pubTime":"2025-12-18 21:30","pubTimestamp":1766064622,"startTime":"0","endTime":"0","summary":"Aprea Therapeutics首席执行官致股东信，强调2025年管线进展及2026年展望","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584600792","title":"Aprea Therapeutics, Inc.2025财年第三财季实现净利润-2.97百万美元，同比增加21.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584600792","media":"市场透视","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584600792?lang=zh_cn&edition=full","pubTime":"2025-11-18 10:00","pubTimestamp":1763431244,"startTime":"0","endTime":"0","summary":"11月18日，Aprea Therapeutics, Inc.公布财报，公告显示公司2025财年第三财季净利润为-2.97百万美元，同比增加21.43%；其中营业收入为1848.00美元，同比减少99.48%，每股基本收益为-0.47美元。机构评级：截至2025年11月18日，当前有2家机构对Aprea Therapeutics, Inc.目标价做出预测，其中目标均价为10.50美元，其中最低目标价为10.00美元，最高目标价为11.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111810005197700d1b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111810005197700d1b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2518627618","title":"Aprea Therapeutics, Inc.盘中异动 股价大涨6.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518627618","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518627618?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:24","pubTimestamp":1741616689,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时24分，Aprea Therapeutics, Inc.股票出现异动，股价快速上涨6.27%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.52%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Aeon Biopharma, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Dogwood Therapeutics, Inc.较为活跃，换手率分别为3414.97%、722.01%、415.62%，振幅较大的相关个股有Dogwood Therapeutics, Inc.、Scisparc Ltd.、Biodexa Pharmaceuticals Plc，振幅分别为41.36%、40.24%、39.34%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022244998a2aa2e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022244998a2aa2e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514869463","title":"Aprea Therapeutics, Inc.盘中异动 急速上涨5.20%报2.68美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514869463","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514869463?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:49","pubTimestamp":1740667763,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时49分，Aprea Therapeutics, Inc.股票出现波动，股价急速拉升5.20%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.89%。其相关个股中，Cero Therapeutics Holdings Inc C/Wts 13/02/2029 、Nutriband Inc C/Wts 、Tiziana Life Sciences Ltd涨幅较大，Quoin Pharmaceuticals Ltd、Moleculin Biotech, Inc.、Aeon Biopharma, Inc.较为活跃，换手率分别为471.13%、96.23%、84.99%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Biorestorative Therapies, Inc.、Tevogen Bio Holdings Inc C/Wts 14/02/2029 ，振幅分别为59.85%、30.36%、21.99%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224923abdf7328&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250227224923abdf7328&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2514090349","title":"Aprea Therapeutics, Inc.盘中异动 早盘快速上涨5.88%报2.70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090349","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514090349?lang=zh_cn&edition=full","pubTime":"2025-02-25 22:35","pubTimestamp":1740494150,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时35分，Aprea Therapeutics, Inc.股票出现波动，股价快速拉升5.88%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.44%。其相关个股中，Moleculin Biotech, Inc.、Silexion Therapeutics Corp、Adial Pharmaceuticals, Inc涨幅较大，Gt Biopharma, Inc.、Moleculin Biotech, Inc.、Adial Pharmaceuticals, Inc较为活跃，换手率分别为774.32%、490.60%、259.23%，振幅较大的相关个股有Adial Pharmaceuticals, Inc、Gt Biopharma, Inc.、Moleculin Biotech, Inc.，振幅分别为20.51%、18.23%、15.89%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223550962ff385&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223550962ff385&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2513722499","title":"Aprea Therapeutics, Inc.盘中异动 早盘急速上涨5.92%报2.78美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2513722499","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513722499?lang=zh_cn&edition=full","pubTime":"2025-02-24 22:35","pubTimestamp":1740407705,"startTime":"0","endTime":"0","summary":"北京时间2025年02月24日22时35分，Aprea Therapeutics, Inc.股票出现异动，股价快速拉升5.92%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.09%。其相关个股中，Aspire Biopharma Holdings Inc C/Wts 14/02/2030 、Psyence Biomedical Ltd C/Wts 25/01/2029、Addex Therapeutics Limited涨幅较大，Aditxt, Inc.、Biodexa Pharmaceuticals Plc、Acurx Pharmaceuticals, Inc.较为活跃，换手率分别为42.24%、24.21%、17.78%，振幅较大的相关个股有Telix Pharmaceutic、Gossamer Bio, Inc.、Summit Therapeutics Inc.，振幅分别为15.85%、14.69%、14.51%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223505abdb0eb2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224223505abdb0eb2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","LENZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2512143665","title":"Aprea Therapeutics, Inc.盘中异动 股价大跌5.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512143665","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2512143665?lang=zh_cn&edition=full","pubTime":"2025-02-20 03:34","pubTimestamp":1739993691,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日03时34分，Aprea Therapeutics, Inc.股票出现波动，股价急速下挫5.44%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.51%。其相关个股中，Surrozen Inc C/Wts 01/08/2031 、Osr Holdings, Inc.、Osr Holdings Inc C/Wts 02/09/2028 涨幅较大，Aditxt, Inc.、Alzamend Neuro, Inc.、Osr Holdings, Inc.较为活跃，换手率分别为688.41%、255.53%、231.18%，振幅较大的相关个股有Surrozen Inc C/Wts 01/08/2031 、Osr Holdings Inc C/Wts 02/09/2028 、Osr Holdings, Inc.，振幅分别为280.70%、267.43%、159.49%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220033451a24c3162&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220033451a24c3162&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","APRE","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2510333469","title":"Aprea Therapeutics, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510333469","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510333469?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:05","pubTimestamp":1739286310,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时05分，Aprea Therapeutics, Inc.股票出现波动，股价急速下挫5.01%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为1.41%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Lipella Pharmaceuticals Inc.涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2491.97%、706.54%、319.82%，振幅较大的相关个股有Dominari Holdings Inc.、In8Bio, Inc.、Ocean Biomedical, Inc.，振幅分别为45.29%、37.99%、33.04%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230510961f4e1e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211230510961f4e1e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","APRE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509775210","title":"Aprea Therapeutics, Inc.盘中异动 急速跳水5.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2509775210","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509775210?lang=zh_cn&edition=full","pubTime":"2025-02-08 04:21","pubTimestamp":1738959661,"startTime":"0","endTime":"0","summary":"北京时间2025年02月08日04时21分，Aprea Therapeutics, Inc.股票出现波动，股价大幅下跌5.66%。Aprea Therapeutics, Inc.股票所在的生物技术行业中，整体跌幅为0.76%。其相关个股中，Conduit Pharmaceuticals Inc.、Surrozen Inc C/Wts 01/08/2031 、Sionna Therapeutics, Inc.涨幅较大，Conduit Pharmaceuticals Inc.、Tonix Pharmaceuticals Holding Corp.、Lipella Pharmaceuticals Inc.较为活跃，换手率分别为8972.52%、184.16%、164.09%，振幅较大的相关个股有Neurosense Therapeutics Ltd C/Wts 10/11/2026 、Conduit Pharmaceuticals Inc.、Lexaria Bioscience Corp C/Wts 14/01/2026 ，振幅分别为130.43%、93.55%、66.67%。Aprea Therapeutics, Inc.公司简介：Aprea Therapeutics Inc是一家临床生物制药公司，致该小组通过合成的致死率专注于精确肿瘤学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208042101abc673c5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250208042101abc673c5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["APRE","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.aprea.com","stockEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0621},{"period":"3month","weight":0.0392},{"period":"6month","weight":-0.2741},{"period":"1year","weight":-0.4683},{"period":"ytd","weight":0.0722}],"compareEarnings":[{"period":"1week","weight":0.0124},{"period":"1month","weight":0.0493},{"period":"3month","weight":0.0887},{"period":"6month","weight":0.0981},{"period":"1year","weight":0.2695},{"period":"ytd","weight":0.1005}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Aprea Therapeutics, Inc.于2019年5月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，致力于开发和商业化新型癌症疗法，重新激活突变型p53肿瘤抑制蛋白。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.06034},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.033286},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.111168},{"month":4,"riseRate":0.142857,"avgChangeRate":-0.117728},{"month":5,"riseRate":0.142857,"avgChangeRate":-0.090283},{"month":6,"riseRate":0.333333,"avgChangeRate":0.023066},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.044399},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.005221},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.052829},{"month":10,"riseRate":0.333333,"avgChangeRate":0.013865},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.091344},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.053133}],"exchange":"NASDAQ","name":"Aprea Therapeutics, Inc.","nameEN":"Aprea Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Aprea Therapeutics, Inc.(APRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Aprea Therapeutics, Inc.(APRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Aprea Therapeutics, Inc.,APRE,Aprea Therapeutics, Inc.股票,Aprea Therapeutics, Inc.股票老虎,Aprea Therapeutics, Inc.股票老虎国际,Aprea Therapeutics, Inc.行情,Aprea Therapeutics, Inc.股票行情,Aprea Therapeutics, Inc.股价,Aprea Therapeutics, Inc.股市,Aprea Therapeutics, Inc.股票价格,Aprea Therapeutics, Inc.股票交易,Aprea Therapeutics, Inc.股票购买,Aprea Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Aprea Therapeutics, Inc.(APRE)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Aprea Therapeutics, Inc.(APRE)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}